 1. Any current or past significant medical conditions that, according to the investigator, might affect pharmacodynamic response to the study drugs, such as significant systemic or respiratory diseases e.g., cystic fibrosis, bronchiectasis, emphysema, nonreversible pulmonary diseases, other than asthma. 